APLD vs MRNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 19, 2026

APLD

53.4
AI Score
VS
APLD Wins

MRNA

52.9
AI Score

Investment Advisor Scores

APLD

53score
Recommendation
HOLD

MRNA

53score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric APLD MRNA Winner
Revenue 352.56M 534.00M MRNA
Net Income -101.93M -2.13B APLD
Net Margin -28.9% -397.9% APLD
Operating Income -111.64M -2.20B APLD
ROE -6.4% -31.4% APLD
ROA -1.6% -19.4% APLD
Total Assets 6.25B 10.96B MRNA
Cash 1.73B 1.72B APLD
Current Ratio 2.38 2.29 APLD

Relative Price Performance (Last 90 Days)

APLD 1M: +4.9% · 3M: -37.0% MRNA 1M: +25.8% · 3M: +199.3%

Current Technical Phase

APLD

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 54

RSI (14): 54.4 · Price: $28.54

MRNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (47.8% over 20 days), RSI 72

RSI (14): 72.2 · Price: $182.56

Fundamentals Snapshot

Metric APLD MRNA
Market Cap
Forward P/E -25.4 -38.1
Trailing P/E
Revenue (TTM)
Revenue Growth 4.1% 0.0%
Gross Margin 0.3% -0.7%
Operating Margin -0.5% -5.6%
EPS -0.91 -7.98
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, APLD is currently the stronger investment candidate, winning 7 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.